# Tectonic Therapeutic, Inc.: overview TECX · Nasdaq · CIK 1681087 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/tecx.md) · [Financials](/companies/tecx/financials.md) · [Filings](/companies/tecx/filings.md) · [Insiders](/companies/tecx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.20)](/filings/0001193125-25-269701.md) | not reported | [(0.93)](/filings/0001193125-26-212016.md) | [(1.07)](/filings/0001193125-26-338062.md) | [(1.02)](/filings/0001193125-25-269701.md) | not reported | [(1.34)](/filings/0001193125-26-212016.md) | [(1.18)](/filings/0001193125-26-338062.md) | | Free cash flow | $m | [(19.8) d](/filings/0001193125-25-269701.md) | [(16.8) d](/filings/0001193125-26-076793.md) | [(13.1)](/filings/0001193125-26-212016.md) | [(14.7) d](/filings/0001193125-26-338062.md) | [(18.0) d](/filings/0001193125-25-269701.md) | [(14.5) d](/filings/0001193125-26-076793.md) | [(18.4)](/filings/0001193125-26-212016.md) | [(21.5) d](/filings/0001193125-26-338062.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(2.78)](/filings/0000950170-23-009527.md) | [(2.42)](/filings/0000950170-24-031635.md) | [(33.76)](/filings/0000950170-25-042648.md) | [(6.83)](/filings/0001193125-26-076793.md) | [(4.05)](/filings/0001193125-26-076793.md) | | Free cash flow | $m | [(100)](/filings/0000950170-23-009527.md) | [(97.5)](/filings/0000950170-24-031635.md) | [(41.0)](/filings/0000950170-25-042648.md) | [(59.2)](/filings/0001193125-26-076793.md) | [(60.3)](/filings/0001193125-26-076793.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tecx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $97.3m | 2,830,378 | | Added +13,884 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $41.4m | 1,204,891 | | Unchanged | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $39.3m | 1,141,824 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $29.7m | 862,592 | | Added +2,240 | | [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $27.5m | 800,726 | | Added +152,983 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $20.9m | 607,788 | | Unchanged | | [5AM Venture Management, LLC](/funds/1799883.md) | 2026-06-30 | $20.9m | 606,660 | | Unchanged | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $20.5m | 596,900 | | Reduced −250,251 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $16.8m | 488,805 | | Added +15,273 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $14.6m | 425,000 | | Added +97,000 | ## Recent filings [All 572 filings](/companies/tecx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 17:19 ET | [8-K](/filings/0001193125-26-407823.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-407823 | | 2026-08-06 | 16:16 ET | [10-Q](/filings/0001193125-26-338062.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338062 | | 2026-08-06 | 16:10 ET | [8-K](/filings/0001193125-26-338000.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338000 | | 2026-06-10 | 17:08 ET | [8-K](/filings/0001193125-26-266040.md) | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-266040 | | 2026-05-07 | 16:23 ET | [8-K](/filings/0001193125-26-212069.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-212069 | | 2026-05-07 | 16:19 ET | [10-Q](/filings/0001193125-26-212016.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212016 | | 2026-04-24 | 16:39 ET | [DEF 14A](/filings/0001193125-26-177467.md) | Proxy statement, period 2026-06-08 | 0001193125-26-177467 | | 2026-04-23 | 16:30 ET | [8-K](/filings/0001193125-26-173829.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-173829 | | 2026-02-26 | 16:26 ET | [8-K](/filings/0001193125-26-076843.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-076843 | | 2026-02-26 | 16:21 ET | [10-K](/filings/0001193125-26-076793.md) | Annual report, period 2025-12-31 | 0001193125-26-076793 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-076793.md), filed Feb 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1681087 - Tickers: TECX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: NY - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 10:58 ET. No prices; not investment advice.